Rebiotix, one of a handful of major companies working on microbiome-based drugs, announced Wednesday that its donor stool-based therapeutic for deadly Clostridium difficile infections was successful — the first-ever unveiling of positive Phase 3 data for any company in the nascent microbiome industry.

The drug, which is delivered as an enema, significantly reduced the number of people who had diarrhea within eight weeks of their treatment, which is one sign that a C. difficile infection may be recurring, the company said. But the data are incredibly limited — they don’t show comparison to placebo group or other relative metrics. Rebiotix, which is owned by Ferring Pharmaceuticals, based the results on a preliminary analysis which did not include any other data or detailed statistics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy